Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06067984 · ClinicalTrials.gov registry record · Phase 3
An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia
A Phase 3 study, sponsored by Click Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 73
- Enrollment target
NCT06067984 is a Phase 3 study that has completed, run by Click Therapeutics. The registered enrollment target is 73 participants.
The verdict
NCT06067984, a Phase 3 study, has completed, sponsored by Click Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 73 participants
- Enrollment target
Study Summary
The purpose of the proposed an open label extension (OLE) study is to evaluate the maintained efficacy and safety of a second consecutive course of Click Therapeutics Study App as an adjunct treatment to standard of care (SOC) in participants who were on the Study App and have recently completed the Click Therapeutics Randomized Clinical Trial NCT05838625.
Interventions
- DEVICE Study App
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2023-09-12 |
| Est. Completion | 2025-08-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06067984
The ClinicalTrials.gov registry entry for NCT06067984 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Click Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Study App is the first listed.
NCT06067984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06067984 about?
NCT06067984 is a clinical study titled "An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia". The purpose of the proposed an open label extension (OLE) study is to evaluate the maintained efficacy and safety of a second consecutive course of Click Therapeutics Study App as an adjunct treatment to standard of care (SOC) in participants who were on the Study App and have recently completed the...
What is the current status of trial NCT06067984?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 73 participants. The study started on 2023-09-12. Estimated completion is 2025-08-22.
What interventions are being tested in trial NCT06067984?
The interventions under investigation include: Study App (DEVICE).
Who is sponsoring clinical trial NCT06067984?
This trial is sponsored by Click Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.